Page tree
Skip to end of metadata
Go to start of metadata

Date: June 26, 2020


Time: 12pm ET


Attendees

Name

Organization

Keri Reardon

Alliance for Clinical Trials in Oncology Foundation

Cassandra O'Connell

Alliance for Clinical Trials in Oncology Foundation

Devon Adams

American Cancer Society

Mark Fleury

American Cancer Society - Cancer Action Network

Kelly Durden

American Cancer Society - Cancer Action Network

Robert Miller

American Society of Clinical Oncology

Joseph Rogers

CDC

Wendy Blumenthal

CDC

Brian Gardner

Cerner

Susan Stiles

Cerner

Ryan Bernard

Epic

Leah Nida

Flatiron Health

Kerry Rowe

Intermountain Healthcare

Margaret Van Meter

Intermountain Healthcare

Roger Mueller

Mayo

Rimma Belenkaya

Memorial Sloan Kettering Cancer Center

Tatyana Sandler

Memorial Sloan Kettering Cancer Center

Steve Bratt

MITRE

Salim Semy

MITRE

Michelle Casagni

MITRE

Anthony DiDonato

MITRE

Andre Quina

MITRE

Caroline Potteiger

MITRE

Jenn Holmes

MITRE

Zeshan Rajput

MITRE

George Neyarapally

MITRE

Zach Lister

MITRE

Carmela Couderc

MITRE

Benjamin Langley

MITRE

Gregory Shemancik

MITRE

Nicole Ng

MITRE

Sharon Sebastian

MITRE

Rob Dingwell

MITRE

Ammu Irivinti

MITRE

May Terry

MITRE

Jocelyn Keegan

Point-of-Care Partners

Trevor Pugh

Princess Margaret Cancer Center

Kaushal Parekh

Roche

Wendy Ver Hoef

Samvit Solutions

Elly Cohen

UCSF

Ben Tsai

UCSF

Amy Lin

UCSF

Melanie Hullings

UT Southwestern

Shaalan Beg

UT Southwestern

Tarun Kumar

Vizlitics

Sharon Hensley Alford

Vizlitics

Shilpa Mahatma

Vizlitics

Galaxy A7 (2018)

Vizlitics

Planned Agenda Topics

Time

Topic

Presenters

12:00 – 12:05

Welcome & Community Announcements

Zeshan Rajput (MITRE)

12:05 – 12:10

CodeX Updates

Steve Bratt (MITRE)

12:10 – 12:20

CodeX Use Case Spotlight: Patient – Clinical Trials Matching

Caroline Potteiger (MITRE), Salim Semy (MITRE), Zach Lister (MITRE)

12:20 – 12:50

MSK and OHDSI Standardization Challenge

Rimma Belenkaya (MSK)

12:50 – 1:00

Community Discussion

All attendees welcome

Welcome & Announcements – Zeshan Rajput, MITRE

Zeshan welcomed new members to our Community of Practice. He discussed how CodeX takes a use case driven approach toward the successful implementation of mCODE, which is where the Community of Practice (CoP) comes into play. The CoP is a community that allows organizations to discuss their experiences, with a focus on the implementation of mCODE.

 

CodeX Updates – Steve Bratt, MITRE

 

Steve touched on MITRE’s engagement with Point-of-Care Partners to provide insight on how to set up a thriving community. He also spoke about how CodeX is currently focused on cancer efforts and is diverse in its implementations and use cases.


Integrated Trial Matching for Cancer Patients and Providers – Mark Fleury ACS-CAN & Zach Lister, MITRE

 

Mark began discussing the overarching problem: if you are a patient diagnosed with cancer, and the hospital doesn’t have any clinical trials available, then you are typically told to find clinical trials on your own. On average, only 23% of patients will be able to enroll in on-site clinical trials, thus most trials take a very specific sub-section of the population, since these trial matching services are tough to find and use. The Integrated Trial Matching for Cancer Patients and Providers Project thus proposes, at the request of either the patient or provider, the ability to export a finite set of variables in a de-identified manner using mCODE data elements. This data would then be sent to a third-party matching service, and finally sent back to the EHR for the patient and/or provider to review.


Zach then followed this discussion with a DEMO of the project.


MSK and OHDSI Standardization Challenge – Rimma Belenkaya, Memorial Sloan Kettering Cancer Center belenkar@mskcc.org


Rimma is the head of Memorial Sloan Kettering Cancer Center and co-lead of the OHDSI Oncology Workgroup – a collaborative founded in 2009 that works on supporting a large community of stakeholders to support the observational research of real-world data. OHDSI, at its foundation, is a standardized data representation; the common data model uses clinical data, health system data, drug data, economic data, and a standardized vocabulary known as OMOP. One key difference between OMOP and mCODE is that OMOP’s vocabulary is mostly composed of reused terminology standards – by selecting standards based on comprehensive, high-volume use. The team looks to leverage OMOP – as well as a few other data standards, such as ICD-0 and NAACCR – to create the base-level of the cancer diagnosis language for the model and to work on analytic use cases and research.


The core challenge to address with OHDSI is the problematic way of generating cohorts for clinical studies – only about 20% of the Memorial Sloan Kettering Cancer Center (MSKCC) patient population is on clinical trials. This is very detrimental because it doesn’t create opportunity for researchers to incorporate a larger group of patients. Thus, OHDSI has started working on standardizing and addressing the oncology challenge for representing cancer data to support observational cancer research. One of the team’s goals is to extend the vocabulary, develop ETL for tumor registry and EHR data, and create analytic use cases. Currently, when the team is looking at an individual diagnosis, they can immediately connect to the other diagnostic attributes that apply to this particular diagnosis. The first OMOP Oncology module was released in 2019.


Moving forward, Memorial Sloan Kettering Cancer Center looks to build mCODE into their cancer database which will support cancer research at MSKCC – by standardizing MSKCC’s cancer database using mCODE.


Community Discussion / Questions:

 

Question: Kaushal Parekh, Roche →  “How do you handle the challenge of some of the more difficult EHR data?”

Answer: Rimma Belenkaya, MSKCC →  “This is why we are using SNOMED as part of the vocabulary. To represent the modules, MSK is using the SNOMED vocabulary and others like ICD-0, NAACCR for this reason.”


Question: Trevor Pugh, Princess Margaret Cancer Center →  “How is genomic data transmitted?”

Answer: Caroline Potteiger, MITRE →  “Tumor marker profiles are what we are using for genomic testing.”


Community of Practice – June Meeting Adjourned

  • No labels